Edgar Filing: Cellular Biomedicine Group, Inc. - Form 4

Cellular Biomedicine Group, Inc. Form 4 October 06, 2014

October 06, 2	014											
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION										OMB APPROVAL		
	Washington, D.C. 20549								OMB Number:	3235-0287		
Check this if no long subject to Section 16 Form 4 or Form 5 obligation may conti <i>See</i> Instru 1(b).	Filed pur snue.	suant to S (a) of the l	T OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES ht to Section 16(a) of the Securities Exchange Act of 1934, f the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940							January 31, 2005 average rs per 0.5		
(Print or Type R	esponses)											
Chan Andrew K Symbol				Name and Biomedic]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
				f Earliest Transaction Day/Year) 014				Director 10% Owner Officer (give title X Other (specify below) below) SVP Corp Bus Dev				
				ndment, Date Original th/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
PALO ALTO	D, CA 94301							Form filed by M Person	Iore than One Re	porting		
(City)	(State)	(Zip)	Table	e I - Non-De	erivative S	ecurit	ies Acq	uired, Disposed of	, or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	2. Transaction Dat (Month/Day/Year)	Executio any	med n Date, if Day/Year)	3. Transactio Code (Instr. 8) Code V	n(A) or Dis (D) (Instr. 3, 4	sposed	of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
Common Stock	09/09/2014			J <u>(1)</u>	22,822	А	\$0	152,376	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

I S	. Title of Derivative Security Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Instr. 8	5. tionNumber of Derivativ Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Expiration D (Month/Day, e			le and unt of rlying ities . 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
					Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Bus Dev

Edgar Filing: Cellular Biomedicine Group, Inc. - Form 4

Reporting Owners

Reporting Owner Name / A	ddress	Relationships					
reporting o wher runne /	Direc	ctor	10% Owner	Officer	Other		
Chan Andrew K 530 UNIVERSITY AVEN PALO ALTO, CA 94301	UE, #17				SVP Corp I		
Signatures							
/s/ Andrew Chan	10/06/2014						
<u>**</u> Signature of	Date						

**Signature of Reporting Person

5

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Reporting Person received 22,822 shares of common stock, par value \$0.001 per share (?Common Stock?), of Cellular Biomedicine Group, Inc. from Global Health Investment Holdings Ltd. in a pro rata distribution to its members.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.